

**THE PENDING CLAIMS**

Claims 108-131, 133-134, 146, 148, 151-156, 158-159, 161-173, 175-176, 178-181, 183-193, 195-198 and 200-231 were pending, claims 175, 176 and 190 have been deleted, claims 232-234 added, and various claims amended. Accordingly, Claims 108-131, 133-134, 146, 148, 151-156, 158-159, 161-173, 178-181, 183-189, 191-193, 195-198 and 200-234 remain pending in this case. The applicant requests reconsideration of and allowance of the pending claims in view of the present amendments and the agreement reached with the examiner.

**THE SEQUENCE LISTING**

A Substitute Sequence Listing is being couriered to the examiner, who is requested to substitute it for that filed May 4, 2000. A Declaration is also enclosed.

**THE SPECIFICATION**


The applicant has delete language relating to sequences and certain targets that were objected to.

**THE CLAIMS**

The claims have been amended as agreed to during the interview and, therefore, believed to be in allowable form.

In view of the foregoing amendments and remarks, and of the prior filing of a Substitute Sequence Listing and Declaration, as well as a Petition for Extension of Time and a Notice of Appeal with payment of the requisite fees, this application is believed to be in condition for examination and allowance. Early notice to this respect is solicited.

Respectfully submitted.  
EPIGENESIS PHARMACEUTICALS, INC



Viviana Amzel, Ph. D.  
Reg. No. 30930  
Attorney for Applicant(s)

May 1 2001  
Date

7 Clarke Drive  
Cranbury, NJ 08512  
609-409-3035 Ph.  
413-845-7530 Fax